PMC:7172841 / 341-585 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":139,"end":149},"obj":"Body_part"},{"id":"T2","span":{"begin":194,"end":203},"obj":"Body_part"},{"id":"T3","span":{"begin":223,"end":226},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84795"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":7,"end":25},"obj":"Disease"},{"id":"T7","span":{"begin":61,"end":69},"obj":"Disease"},{"id":"T8","span":{"begin":139,"end":169},"obj":"Disease"},{"id":"T9","span":{"begin":171,"end":174},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005046"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":150,"end":160},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T3","span":{"begin":188,"end":193},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":204,"end":211},"obj":"Chemical"},{"id":"T2","span":{"begin":227,"end":229},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":38,"end":54},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T3","span":{"begin":139,"end":160},"obj":"http://purl.obolibrary.org/obo/GO_0042116"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":27,"end":99},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T6","span":{"begin":7,"end":13},"obj":"UBERON:0002405"},{"id":"T7","span":{"begin":38,"end":44},"obj":"UBERON:0002405;GO:0006955"},{"id":"T8","span":{"begin":45,"end":54},"obj":"GO:0006955"},{"id":"T9","span":{"begin":61,"end":69},"obj":"SP_7"},{"id":"T10","span":{"begin":139,"end":149},"obj":"CL:0000235;GO:0042116"},{"id":"T11","span":{"begin":150,"end":160},"obj":"GO:0042116"},{"id":"T12","span":{"begin":188,"end":193},"obj":"SP_6;NCBITaxon:9606"},{"id":"T13","span":{"begin":194,"end":203},"obj":"CL:0000738"},{"id":"T14","span":{"begin":204,"end":211},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T15","span":{"begin":223,"end":226},"obj":"PR:000029150"},{"id":"T16","span":{"begin":231,"end":241},"obj":"GO:0010467"},{"id":"T67700","span":{"begin":7,"end":13},"obj":"UBERON:0002405"},{"id":"T7839","span":{"begin":38,"end":44},"obj":"UBERON:0002405;GO:0006955"},{"id":"T23482","span":{"begin":45,"end":54},"obj":"GO:0006955"},{"id":"T94326","span":{"begin":61,"end":69},"obj":"SP_7"},{"id":"T55692","span":{"begin":139,"end":149},"obj":"CL:0000235;GO:0042116"},{"id":"T76896","span":{"begin":150,"end":160},"obj":"GO:0042116"},{"id":"T56154","span":{"begin":188,"end":193},"obj":"SP_6;NCBITaxon:9606"},{"id":"T45303","span":{"begin":194,"end":203},"obj":"CL:0000738"},{"id":"T92944","span":{"begin":204,"end":211},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T58214","span":{"begin":223,"end":226},"obj":"PR:000029150"},{"id":"T41859","span":{"begin":231,"end":241},"obj":"GO:0010467"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}

{"project":"LitCovid-PubTator","denotations":[{"id":"44","span":{"begin":70,"end":78},"obj":"Species"},{"id":"45","span":{"begin":104,"end":112},"obj":"Species"},{"id":"50","span":{"begin":188,"end":193},"obj":"Species"},{"id":"57","span":{"begin":7,"end":25},"obj":"Disease"},{"id":"58","span":{"begin":61,"end":69},"obj":"Disease"},{"id":"59","span":{"begin":95,"end":98},"obj":"Disease"},{"id":"60","span":{"begin":118,"end":121},"obj":"Disease"},{"id":"61","span":{"begin":139,"end":169},"obj":"Disease"}],"attributes":[{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"Tax:9606"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"Tax:9606"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:9606"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D007154"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:C000657245"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D055501"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression ac"}